0001493152-22-029808.txt : 20221028 0001493152-22-029808.hdr.sgml : 20221028 20221028132932 ACCESSION NUMBER: 0001493152-22-029808 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20221028 DATE AS OF CHANGE: 20221028 EFFECTIVENESS DATE: 20221028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900031917 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-463149 FILM NUMBER: 221340533 BUSINESS ADDRESS: STREET 1: 10025 INVESTMENT DRIVE STREET 2: SUITE 250 CITY: KNOXVILLE STATE: TN ZIP: 37932 BUSINESS PHONE: 865-769-4011 MAIL ADDRESS: STREET 1: 10025 INVESTMENT DRIVE STREET 2: SUITE 250 CITY: KNOXVILLE STATE: TN ZIP: 37932 FORMER COMPANY: FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020417 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 D 1 primary_doc.xml X0708 D LIVE 0000315545 PROVECTUS BIOPHARMACEUTICALS, INC. 800 S. GAY STREET SUITE 1610 KNOXVILLE TN TENNESSEE 37929 866-594-5999 DELAWARE None PROVECTUS PHARMACEUTICALS INC ZAMAGE DIGITAL IMAGING INC SPM GROUP INC Corporation true Webster Bailey 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Director Bruce Horowitz 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Executive Officer Director John Lacey, III 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Director Ed Pershing 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Director Dominic Rodrigues 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Director Heather Raines 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Executive Officer Eric Wachter 800 S. Gay Street Suite 1610 Knoxville TN TENNESSEE 37929 Executive Officer Pharmaceuticals $1 - $1,000,000 06b false 2022-09-23 false true true false 0 5000000 317500 4682500 false 2 0 0 0 Proceeds will be used to fund the Company's drug discovery and development program, as currently constituted and envisioned, and to fund the Company's general and administrative expenses. false PROVECTUS BIOPHARMACEUTICALS, INC. /s/ Heather Raines Heather Raines Chief Financial Officer 2022-10-28